Publication | Closed Access

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial

Antifungal AgentIsavuconazole Versus VoriconazoleAntifungal AgentsFungal BiologyNon-inferiority TrialMicrobiologyInvasive Mould DiseaseMedicineAntimicrobial ResistanceFungal Pathogen